Novartis (NVS) said Thursday that its phase 3b study of Fabhalta in adult patients with paroxysmal nocturnal hemoglobinuria, or PNH, showed "statistically significant and clinically meaningful" improvements in hemoglobin levels.
The trial enrolled 52 patients who received Fabhalta for 24 weeks and the primary endpoint was change from baseline hemoglobin levels, the company said.
Most patients under trial achieved normal or near-normal levels of hemoglobin and no patient required transfusion during the study, Novartis said, adding that patients also reported significant improvements in fatigue.
Novartis shares were up more than 1% in recent premarket activity Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.